Envisia Therapeutics, Inc

 Company Summary:
  • Envisia Therapeutics, formed by Liquidia Technologies, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma.
Transaction Overview: Significance of the Transaction:
  • With ENV515, Envisia brings a potentially revolutionary approach to advancing glaucoma pharmacotherapy
  • In addition to ENV515, Envisia is using its proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology platform to create a pipeline of small and large molecule particle-based ocular therapeutics
Healthios Role:
  • Healthios served as strategic adviser to Liquidia on the “Spin-Off” and financing Envisia
  • This transaction highlights Healthios commitment to capital formation for emerging growth companies, our success in completing complex transaction, and our dedication to deep, long-term relationships.